Clinical Trial Update: Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III [Phase 3]

View source ↗

Summary

A Phase III trial comparing bevacizumab alone versus dose-dense temozolomide followed by bevacizumab in recurrent glioblastoma is ongoing or status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Progression
• Recurrence

Drugs mentioned

• Bevacizumab (bevacizumab)
• temozolomide (dose-dense) (temozolomide)

Snippet

Sponsor: Kyorin University | Conditions: Glioblastoma, Recurrence | Phase 3 | Status: UNKNOWN